Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JORGE A GARCIA ZUAZAGA

Allopathic & Osteopathic Physicians Dermatology MOHS-Micrographic Surgery

NPI
1407979529
CMS profile
830298
Location
CONCORD TOWNSHIP, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$7,268.57

21 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JORGE A GARCIA ZUAZAGA

NPI 1407979529 · CMS profile ID 830298

Allopathic & Osteopathic Physicians / Dermatology / MOHS-Micrographic Surgery

CONCORD TOWNSHIP, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1407979529?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JORGE A GARCIA ZUAZAGA, NPI 1407979529, CMS profile ID 830298. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1407979529?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JORGE A GARCIA ZUAZAGA, NPI 1407979529, CMS profile ID 830298. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1407979529?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JORGE A GARCIA ZUAZAGA, NPI 1407979529, CMS profile ID 830298, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1407979529?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

21 matching records · $7,268.57 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 21 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–21 of 21.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GENZYME CORPORATION $135.4211/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694260467 CMS
GENZYME CORPORATION $2,730.0011/07/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694261001 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $13.5410/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684578571 CMS
Novartis Pharmaceuticals Corporation $13.1710/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659630405 CMS
Novartis Pharmaceuticals Corporation $17.2010/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659630403 CMS
Novartis Pharmaceuticals Corporation $14.9408/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659630407 CMS
GENZYME CORPORATION $125.0008/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694161773 CMS
GENZYME CORPORATION $2,730.0008/27/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694161775 CMS
Biofrontera Inc. $13.6707/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 689444273 CMS
Novartis Pharmaceuticals Corporation $12.6107/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659630401 CMS
GENZYME CORPORATION $1,300.0006/28/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694260251 CMS
Journey Medical Corporation $4.7005/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699287195 CMS
Journey Medical Corporation $42.1704/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699287189 CMS
Novartis Pharmaceuticals Corporation $12.3103/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659630399 CMS
Celgene Corporation $24.4603/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672745837 CMS
Novartis Pharmaceuticals Corporation $14.1503/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659630397 CMS
Journey Medical Corporation $11.7202/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699287199 CMS
GENZYME CORPORATION $14.7302/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693909401 CMS
Journey Medical Corporation $13.6401/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699287203 CMS
Novartis Pharmaceuticals Corporation $13.1901/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659630395 CMS
Medimetriks Pharmaceuticals, Inc. $11.9501/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702112310 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $7,268.57 21
PY2020 $1,238.59 7
PY2021 $12,408.53 45
PY2022 $24,381.63 42
PY2023 $84,667.07 52
PY2024 $16,980.08 79
PY2025 $2,421.43 52

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,893,327.58 407
PY2024 Principal investigator $2,667,688.93 422
PY2023 Recipient $18,196.50 3
PY2023 Principal investigator $882,864.23 139
PY2022 Principal investigator $164,380.88 32
PY2021 Recipient $18,912.00 5
PY2021 Principal investigator $12,300.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

32 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Dermavant Sciences, Inc. $1,667.16 12/15/2022 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937434499
Principal investigator 1 Dermavant Sciences, Inc. $1,667.16 12/15/2022 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937434501
Principal investigator 1 Dermavant Sciences, Inc. $1,564.52 12/15/2022 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937434503
Principal investigator 1 Dermavant Sciences, Inc. $1,564.52 12/15/2022 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937434505
Principal investigator 1 ABBVIE INC. $18,825.00 12/07/2022 Non-covered Recipient Entity
APEX CLINICAL RESEARCH
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 889823683
Principal investigator 1 Bausch Health US, LLC $12,000.00 12/05/2022 Non-covered Recipient Entity
Apex Clinical Research Center
A PHASE 4 (PHASE 2 IN EUROPEAN UNION), OPEN-LABEL, MULTICENTER STUDY EVALUATING THE ABSORPTION AND SYSTEMIC PHARMACOKINETICS AND HPA AXIS SUPPRESSION POTENTIAL OF TOPICALLY APPLIED IDP-118 LOTION IN PEDIATRIC SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIA No dispute reported 06/30/2026 960342155
Principal investigator 1 ABBVIE INC. $2,872.88 11/09/2022 Non-covered Recipient Entity
APEX CLINICAL RESEARCH
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms No dispute reported 06/30/2026 889819789
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $39,100.00 11/03/2022 Non-covered Recipient Entity
Apex Clinical Research
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating The Effect Of Deucravacitinib On Quality Of Life In Participants With Plaque Psoriasis In A Community Setting (Artistyk) No dispute reported 06/30/2026 933186503
Principal investigator 1 Incyte Corporation $29,000.00 11/03/2022 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages 12 Years to 18 Years) With Atopic Dermatitis No dispute reported 06/30/2026 905233299
Principal investigator 1 ABBVIE INC. $8,033.00 10/17/2022 Non-covered Recipient Entity
APEX CLINICAL RESEARCH
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms No dispute reported 06/30/2026 889816617
Principal investigator 1 ABBVIE INC. $2,419.96 10/13/2022 Non-covered Recipient Entity
APEX CLINICAL RESEARCH
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms No dispute reported 06/30/2026 889815903
Principal investigator 1 Bausch Health US, LLC $2,500.00 09/22/2022 Non-covered Recipient Entity
Apex Clinical Research Center
A PHASE 4 (PHASE 2 IN EUROPEAN UNION), OPEN-LABEL, MULTICENTER STUDY EVALUATING THE ABSORPTION AND SYSTEMIC PHARMACOKINETICS AND HPA AXIS SUPPRESSION POTENTIAL OF TOPICALLY APPLIED IDP-118 LOTION IN PEDIATRIC SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIA No dispute reported 06/30/2026 960342153
Principal investigator 1 ABBVIE INC. $1,436.44 09/07/2022 Non-covered Recipient Entity
APEX CLINICAL RESEARCH
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms No dispute reported 06/30/2026 889808397
Principal investigator 1 ABBVIE INC. $2,902.36 08/11/2022 Non-covered Recipient Entity
APEX CLINICAL RESEARCH
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms No dispute reported 06/30/2026 889805337
Principal investigator 1 ABBVIE INC. $1,948.36 07/28/2022 Non-covered Recipient Entity
APEX CLINICAL RESEARCH
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms No dispute reported 06/30/2026 889802667
Principal investigator 1 ABBVIE INC. $1,951.04 07/28/2022 Non-covered Recipient Entity
APEX CLINICAL RESEARCH
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms No dispute reported 06/30/2026 889802669
Principal investigator 1 ABBVIE INC. $1,405.62 07/28/2022 Non-covered Recipient Entity
APEX CLINICAL RESEARCH
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms No dispute reported 06/30/2026 889802683
Principal investigator 1 ABBVIE INC. $278.72 07/21/2022 Non-covered Recipient Entity
APEX CLINICAL RESEARCH
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms No dispute reported 06/30/2026 889801845
Principal investigator 1 ABBVIE INC. $1,173.84 07/13/2022 Non-covered Recipient Entity
APEX CLINICAL RESEARCH
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms No dispute reported 06/30/2026 889800353
Principal investigator 1 ABBVIE INC. $199.66 07/13/2022 Non-covered Recipient Entity
APEX CLINICAL RESEARCH
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms No dispute reported 06/30/2026 889800427
Principal investigator 1 ABBVIE INC. $3,446.40 07/07/2022 Non-covered Recipient Entity
APEX CLINICAL RESEARCH
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms No dispute reported 06/30/2026 889799101
Principal investigator 1 ABBVIE INC. $1,409.64 06/16/2022 Non-covered Recipient Entity
APEX CLINICAL RESEARCH
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms No dispute reported 06/30/2026 889796015
Principal investigator 1 ABBVIE INC. $391.24 05/19/2022 Non-covered Recipient Entity
APEX CLINICAL RESEARCH
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms No dispute reported 06/30/2026 889792431
Principal investigator 1 ABBVIE INC. $225.00 05/17/2022 Non-covered Recipient Entity
APEX CLINICAL RESEARCH
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms No dispute reported 06/30/2026 889792257
Principal investigator 1 ABBVIE INC. $2,385.20 05/13/2022 Non-covered Recipient Entity
APEX CLINICAL RESEARCH
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms No dispute reported 06/30/2026 889792185
Principal investigator 1 ABBVIE INC. $1,209.98 05/12/2022 Non-covered Recipient Entity
APEX CLINICAL RESEARCH
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms No dispute reported 06/30/2026 889791745
Principal investigator 1 ABBVIE INC. $7,501.00 04/28/2022 Non-covered Recipient Entity
APEX CLINICAL RESEARCH
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms No dispute reported 06/30/2026 889788961
Principal investigator 1 ABBVIE INC. $5,200.00 03/31/2022 Non-covered Recipient Entity
APEX CLINICAL RESEARCH
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms No dispute reported 06/30/2026 889783069
Principal investigator 1 ABBVIE INC. $1,590.58 03/30/2022 Non-covered Recipient Entity
APEX CLINICAL RESEARCH
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms No dispute reported 06/30/2026 889782763
Principal investigator 1 ABBVIE INC. $3,693.04 02/15/2022 Non-covered Recipient Entity
APEX CLINICAL RESEARCH
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms No dispute reported 06/30/2026 889777217
Principal investigator 1 ABBVIE INC. $1,948.36 01/13/2022 Non-covered Recipient Entity
APEX CLINICAL RESEARCH
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms No dispute reported 06/30/2026 889773881
Principal investigator 1 ABBVIE INC. $2,870.20 01/06/2022 Non-covered Recipient Entity
APEX CLINICAL RESEARCH
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms No dispute reported 06/30/2026 889772233